AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02465034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Paired Associative Stimulation
Description: Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
Study NCT02465034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Median Nerve Stimulation
Description: Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1 milliseconds (ms) rectangular pulses at an intensity to evoke a 1 millivolt (mV) response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
Study NCT02465034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corticocortical Paired Associative Stimulation
Description: Cortico-cortical Paired Associative Stimulation (CC-PAS) is a combination of TMS and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. The interstimulus interval will range from 5-15 ms depending on site of stimulation.TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This CC-PAS may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
Study NCT02465034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Paired Associative Stimulation
Description: The sham PAS is a combination of TMS and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25 Hz for 12 minutes. TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
Study NCT03372954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMAC
Description: retrograde administration on non-selected BMAC via coronary sinus
Study NCT03372954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMAC
Description: retrograde administration on non-selected BMAC via coronary sinus
Study NCT04524975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-008-0045
Description: CD-008-0045 20 mg capsules
Study NCT04524975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules
Study NCT04524975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT01986205 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen (USP oxygen >99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
Study NCT01986205 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Minimal pressure air
Description: Room air delivered in a hyperbaric chamber with minimal pressurization.
Study NCT02350829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance sequence T1 mapping
Description: Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
Study NCT00089180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal T4N5 lotion
Description: Given topically
Study NCT00089180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given topically
Study NCT00089180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00089180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02747628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
Study NCT02747628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal therapeutic system- nicotine.
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
Study NCT02747628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal therapeutic system- melatonin.
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
Study NCT03279237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: May help shrink tumor before surgery.
Study NCT03279237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: May help shrink tumor before surgery.
Study NCT03279237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: May help shrink tumor before surgery.
Study NCT03279237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: May help shrink tumor before surgery.
Study NCT02771587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol and energy drink
Description: Multiple oral dose of alcohol Multiple oral dose of energy drink
Study NCT02771587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Multiple oral dose of alcohol
Study NCT02771587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy drink
Description: Multiple oral dose of energy drink
Study NCT02771587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
Study NCT01245361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3 mg/kg wk 0,2,6
Study NCT01245361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: Group II : Placebo wk 0,2,6
Study NCT03018665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
Study NCT03018665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIAsp30
Description: subcutaneous injection，fit dosage twice a day in three months
Study NCT03018665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: oral，0.85g，twice a day in three months
Study NCT03279237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel may stop cancer cells from growing and spreading.
Study NCT03279237 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: May help shrink tumor.
Study NCT03279237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin may stop cancer cells from growing.
Study NCT04418037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System(DHFS)
Description: We will investigate the feasibility of using the DHFS in hospitalized individuals living with HIV to support ARV adherence.
Study NCT02595229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronator quadratus repair
Description: Suturing of the pronator quadratus muscle
Study NCT02810002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental infantry boot - DEFINITE-REGULATOR
Description: Training: infantry basic training in the experimental boots
Study NCT02810002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control infantry boot
Description: Training: infantry basic training in the control boots
Study NCT04392011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam HCl
Description: Oral syrup, 2 mg/mL
Study NCT04392011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan HBr
Description: Oral liquid capsules, 15 mg
Study NCT04392011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
Study NCT05106803 — intervention group
Intervention type: DRUG
Intervention: ciprofloxacin
Description: Antibiotics used in vitro n the study
Study NCT00774189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin 250 mg tablets
Study NCT03749902 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral misoprostol
Description: * An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~* The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~* If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~* In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency.
Study NCT03749902 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: * Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~* The oxytocin group will not receive misoprostol after the membranes have ruptured.
Study NCT04395768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
Study NCT00774189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin 250 mg tablets
Study NCT03372876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein and carbohydrate supplementation
Description: Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
Study NCT03372876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and carbohydrate supplementation
Description: Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
Study NCT00726830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone hydrochloride
Description: Given orally
Study NCT00726830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine sulfate
Description: Given orally
Study NCT00726830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone hydrochloride
Description: Given orally
Study NCT04395768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT04395768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT04395768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT04395768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT04395768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Citrate
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT03861507 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prostate Brachytherapy
Description: High dose - rate (HDR) brachytherapy
Study NCT04395768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Citrate
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT04395768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT04395768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT04395768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT04395768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study NCT03030261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.
Study NCT03030261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
Study NCT03030261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
Study NCT02793635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Powered Exoskeleton
Description: Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
Study NCT02868437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine self-cross-linked hyaluronic acid gel
Description: intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
Study NCT03108235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOM-HEMP
Description: a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse.
Study NCT03108235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOM-HEMP with smartphone app
Description: a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse. In addition, participants will receive a smartphone app.~The smartphone will be used to monitor their health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference.
Study NCT03108235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
Study NCT02947451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once.
Study NCT02281539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromotus
Study NCT04143607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK120067
Description: ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT04143607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib 250 mg
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT00003509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT04063579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization
Description: Imaging, blood tests, LV pressure measurement
Study NCT04063579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)
Description: Imaging and Blood tests
Study NCT02168920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg/day
Description: Once daily for 10 weeks
Study NCT02168920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/day
Description: Once daily for 10 weeks
Study NCT02168920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg/day
Description: Once daily for 10 weeks
Study NCT02168920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0 mg/day)
Description: Once daily for 10 weeks
Study NCT03250598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: 50 mg single-dose
Study NCT03250598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: 5 mg single-dose
Study NCT03250598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: 200 mg single-dose
Study NCT00541957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavior therapy
Description: 10 sessions over 4 months
Study NCT00541957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication prescribed by PCP
Description: Can include any antidepressant medication